
Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 ...
Topline Results from the AP02 (Inhaled Nintedanib) Phase 1 Clinical Trials Among the Company’s Five Poster Presentations 4.5 Year Long-Term Safety and Efficacy Data Supporting AP01 (Inhaled Pirfenidone) from the ATLAS Open-Label Extension Trial to be …